Dashboard
Manage Tickers

SNDX Syndax Pharmaceuticals Inc

Nasdaq syndax.com


$ 13.68 $ 0.06 (0.44 %)    

Monday, 03-Nov-2025 18:53:26 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 13.76
$ 13.61
$ 13.00 x 50
$ 14.50 x 100
-- - --
$ 8.58 - $ 22.50
4,143,672
na
1.2B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-05-2025 03-31-2025 10-Q
4 03-03-2025 01-01-1970 10-K
5 11-05-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-11-2021 03-31-2021 10-Q
20 03-12-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-05-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-07-2019 12-31-2018 10-K
29 11-05-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-10-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-14-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
11/03/2025 21:12:06

syndax-sees-fy25-rd-plus-selling-general-and-administrative-expenses-380m-385m-vs-370m-390m-prior
Syndax Sees FY25 R&D Plus Selling, General...
11/03/2025 21:04:50

syndax-pharmaceuticals-q3-eps-070-beats-073-estimate-sales-45871m-miss-47976m-estimate
Syndax Pharmaceuticals Q3 EPS $(0.70) Beat...
11/03/2025 21:03:47

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate o...

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

syndax-pharmaceuticalss-earnings-outlook
Syndax Pharmaceuticals's Earnings Outlook
10/31/2025 20:02:50

hc-wainwright--co-reiterates-buy-on-syndax-pharmaceuticals-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Synd...
10/27/2025 10:29:20

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains...

btig-reiterates-buy-on-syndax-pharmaceuticals-maintains-56-price-target
BTIG Reiterates Buy on Syndax Pharmaceutic...
10/27/2025 09:25:30

BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.

why-is-syndax-stock-down-today
Why Is Syndax Stock Down Today?
10/24/2025 20:07:49

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments fro...

syndax-pharmaceuticals-shares-move-lower-despite-fda-approval-as-revuforj-rate-of-complete-remission-plus-cr-with-partial-hematological-recovery-was-23-co-reports-high-rate-of-severe-fatal-side-effects
Syndax Pharmaceuticals Shares Move Lower D...
10/24/2025 18:29:20

syndax-pharmaceuticals-shares-resume-trade
Syndax Pharmaceuticals Shares Resume Trade
10/24/2025 18:20:23

trading-halt-halt-status-updated-at-21500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 2:15:...
10/24/2025 18:15:04

fda-approves-revumenib-for-relapsed-or-refractory-acute-myeloid-leukemia-with-a-susceptible-npm1-mutation
FDA Approves Revumenib For Relapsed Or Ref...
10/24/2025 17:08:47

https://www.fda.gov/drugs/resources-information-approved-drugs/

trading-halt-halted-at-125617-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 12:56:17 p.m. ET -...
10/24/2025 16:56:21

where-syndax-pharmaceuticals-stands-with-analysts
Where Syndax Pharmaceuticals Stands With A...
10/16/2025 14:02:42

hc-wainwright--co-assumes-syndax-pharmaceuticals-at-buy-announces-price-target-of-40
HC Wainwright & Co. Assumes Syndax Pharmac...
10/16/2025 10:49:31

HC Wainwright & Co. analyst Andres Y. Maldonado assumes Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and annou...

btig-reiterates-buy-on-syndax-pharmaceuticals-maintains-56-price-target
BTIG Reiterates Buy on Syndax Pharmaceutic...
09/19/2025 17:11:10

BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.

syndaxs-revuforj-revumenib-added-to-nccn-guidelines-as-category-2a-treatment-for-relapsedrefractory-npm1-mutated-aml-supported-by-augment-101-trial-fda-priority-review-snda-decision-due-oct-25-2025
Syndax's Revuforj (Revumenib) Added To NCC...
09/19/2025 11:02:18

stifel-reinstates-buy-on-syndax-pharmaceuticals-announces-44-price-target
Stifel Reinstates Buy on Syndax Pharmaceut...
09/10/2025 12:33:48

Stifel analyst Bradley Canino reinstates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and announces $44 price target.

goldman-sachs-maintains-buy-on-syndax-pharmaceuticals-raises-price-target-to-24
Goldman Sachs Maintains Buy on Syndax Phar...
09/05/2025 14:52:24

Goldman Sachs analyst Corinne Johnson maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target ...

syndax-gains-attention-with-strong-drug-portfolio-path-to-leukemia-market-growth
Syndax Gains Attention With Strong Drug Po...
09/04/2025 19:17:43

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term pro...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION